Semaglutide vs Tirzepatide: Which is right for you?

Two medications dominate the weight loss conversation: semaglutide and tirzepatide. Both are GLP-1–based therapies used in physician-supervised programs. Both produce meaningful weight loss in clinical trials. They are not interchangeable — your provider selects based on your history, goals, and tolerability.

How they work differently

Semaglutide is a GLP-1 receptor agonist. It mimics a hormone released after eating, slowing gastric emptying and reducing appetite. Brand examples include Wegovy and Ozempic (diabetes indication); compounded semaglutide is used in many telehealth weight-loss programs when clinically appropriate.

Tirzepatide is a dual GIP/GLP-1 agonist (e.g., Zepbound, Mounjaro). It activates two pathways involved in glucose and energy regulation. In trials such as SURMOUNT, average weight loss at higher doses has been among the highest reported for approved obesity pharmacotherapy.

Clinical comparison (high level)

• Semaglutide (STEP trials): Roughly 15–17% mean body-weight reduction at 68 weeks at maintenance doses in adults with obesity, with lifestyle support.
• Tirzepatide (SURMOUNT): Roughly 20–22% mean reduction at the highest studied doses over ~72 weeks in similar populations.
• Onset: Appetite changes often within 1–2 weeks; visible scale changes commonly build over 8–12+ weeks.

Individual results vary. Neither medication replaces nutrition, movement, or follow-up with your care team.

Side effects and tolerability

Both classes commonly cause nausea, fullness, constipation, or diarrhea, especially during dose escalation. Most symptoms improve with time and slower titration. Report severe abdominal pain, persistent vomiting, vision changes, or signs of allergic reaction promptly.

Contraindications include personal or family history of medullary thyroid carcinoma or MEN2, pregnancy, and certain other conditions reviewed in intake.

Cost and access

Brand-name GLP-1 injectables without insurance often exceed $800–$1,200/month. Compounded options and structured telehealth starter programs (often $299–$399 for the first month bundle) can reduce upfront cost — quality of medical oversight and pharmacy sourcing still matter.

Which might be right for you?

Your licensed clinician considers BMI, comorbidities, prior GLP-1 use, side-effect history, cost, and state regulations. There is no correct answer from a blog post — only from your medical review.